Trial · NCT00760019

Inflammation and Vascular Function in Atherosclerosis

NCT00760019, Phase 2, Phase 3, Completed, Brigham and Women's Hospital; results first posted 2017-04-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Inflammation and Vascular Function in Atherosclerosis. Trials, record NCT00760019. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00760019

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Inflammation and Vascular Function in Atherosclerosis
NCT number: NCT00760019
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 58 participants, actual
Lead sponsor: Brigham and Women's Hospital
Conditions: Atherosclerosis
Interventions: salsalate, placebo
First posted: 2008-09-25
Last updated: 2017-05-16
Results first posted: 2017-04-06

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Flow-mediated, Endothelium-dependent Vasodilation	Upon completion of 4 weeks of salsalate and placebo treatment	Flow-mediated, endothelium-dependent vasodilation (percentage increase in brachial artery diameter after a 5 minute ischemic stimulus) measured at the end of placebo treatment and end of salsalate treatment were compared.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Flow-mediated, Endothelium-dependent Vasodilation	Upon completion of 4 weeks of salsalate and placebo treatment	The ultrasound data for two subjects was inadequate for analysis. This determination was made prior to unblinding. The data for these two subjects were discarded, leaving 56 subjects for analysis.	percentage vasodilation	MEDIAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Flow-mediated, Endothelium-dependent Vasodilation	Salsalate		6.8	Inter-Quartile Range 5.2 to 12.0	percentage vasodilation
Flow-mediated, Endothelium-dependent Vasodilation	Placebo		8.7	Inter-Quartile Range 5.4 to 13.5	percentage vasodilation

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Atherosclerosis/Metabolic Syndrome: Salsalate First, Then Plac	15
Overall Study	STARTED	Atherosclerosis/Metabolic Syndrome: Placebo First, Then Salsal	15
Overall Study	STARTED	Healthy Subjects: Salsalate First, Then Placebo	14
Overall Study	STARTED	Healthy Subjects: Placebo First, Then Salsalate	14
Overall Study	COMPLETED	Atherosclerosis/Metabolic Syndrome: Salsalate First, Then Plac	15
Overall Study	COMPLETED	Atherosclerosis/Metabolic Syndrome: Placebo First, Then Salsal	15
Overall Study	COMPLETED	Healthy Subjects: Salsalate First, Then Placebo	14
Overall Study	COMPLETED	Healthy Subjects: Placebo First, Then Salsalate	14
Overall Study	NOT COMPLETED	Atherosclerosis/Metabolic Syndrome: Salsalate First, Then Plac	0
Overall Study	NOT COMPLETED	Atherosclerosis/Metabolic Syndrome: Placebo First, Then Salsal	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Tinnitus	Ear and labyrinth disorders	Salsalate	6	58	6
other	Tinnitus	Ear and labyrinth disorders	Placebo	0	58	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Salsalate	0	58
Total, all-cause mortality	Placebo	0	58
Total, other adverse events	Salsalate	6	58
Total, other adverse events	Placebo	0	58
Total, serious adverse events	Salsalate	0	58
Total, serious adverse events	Placebo	0	58

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
24390146	DERIVED	PubMed
39888728	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Salsalate vs Placebo: deaths from any cause	Trial comparisons
Salsalate vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00760019

GET https://conductscience.org/api/trials/v1/NCT00760019/registered

API reference For AI assistants